mk 0663 has been researched along with etodolac in 3 studies
| Studies (mk 0663) | Trials (mk 0663) | Recent Studies (post-2010) (mk 0663) | Studies (etodolac) | Trials (etodolac) | Recent Studies (post-2010) (etodolac) |
|---|---|---|---|---|---|
| 549 | 173 | 265 | 550 | 125 | 129 |
| Protein | Taxonomy | mk 0663 (IC50) | etodolac (IC50) |
|---|---|---|---|
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 2.649 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.561 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Meena, S; Nageswara Rao, R; Raghuram Rao, A | 1 |
| Pedersen, L; Schmidt, M; Sørensen, HT | 1 |
| Cvijić, S; Dahan, A; Dukhno, O; Partook-Maccabi, M; Porat, D; Vainer, E | 1 |
1 review(s) available for mk 0663 and etodolac
| Article | Year |
|---|---|
An overview of the recent developments in analytical methodologies for determination of COX-2 inhibitors in bulk drugs, pharmaceuticals and biological matrices.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chemistry, Pharmaceutical; Chromatography; Chromatography, High Pressure Liquid; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Drug Industry; Etodolac; Etoricoxib; Lactones; Models, Chemical; Pyrazoles; Pyridines; Spectrophotometry; Sulfonamides; Sulfones; Ultraviolet Rays | 2005 |
2 other study(ies) available for mk 0663 and etodolac
| Article | Year |
|---|---|
Cardiovascular Risks of Diclofenac Versus Other Older COX-2 Inhibitors (Meloxicam and Etodolac) and Newer COX-2 Inhibitors (Celecoxib and Etoricoxib): A Series of Nationwide Emulated Trials.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etodolac; Etoricoxib; Female; Heart Disease Risk Factors; Humans; Meloxicam; Risk Factors | 2022 |
Selective COX-2 inhibitors after bariatric surgery: Celecoxib, etoricoxib and etodolac post-bariatric solubility/dissolution and pharmacokinetics.
Topics: Bariatric Surgery; Bariatrics; Celecoxib; Cyclooxygenase 2 Inhibitors; Etodolac; Etoricoxib; Humans; Solubility | 2023 |